SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

FDA approval provides an important option for those unable to take oral formulation of TPOXX

Shares are moving higher today by 30% in the pre-market on FDA approval of IV TPOXX  for the treatment of small pox.

Shares are trading around $9.50 as I’m wiring this on more than 15,000 trades and 2.3 million plus shares and climbing.

https://www.globenewswire.com/news-release/2022/05/19/2446804/9738/en/SIGA-Receives-Approval-from-the-FDA-for-Intravenous-IV-Formulation-of-TPOXX-tecovirimat.html

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist